



June 16, 2025

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051

**Scrip code: 532531**

**Scrip code: STAR**

Dear Madam/ Sir,

**Sub: Divestment of a dormant step-down whollyowned subsidiary of the Company**

---

We would like to inform you that as part of right sizing of group entities and eliminating dormant entities, Strides Pharma International Limited, a whollyowned subsidiary of the Company, has entered into a Share Transfer Agreement dated June 16, 2025, for divestment of its 100% shareholding in Strides CIS Limited, Cyprus to a third party.

Disclosure under Regulation 30 of SEBI Listing Regulations is enclosed for your information and records.

Thanks & Regards,  
For **Strides Pharma Science Limited**

**Manjula Ramamurthy**  
**Company Secretary & Compliance Officer**  
**ICSI Membership No.: A30515**

*Encl. As above*

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

**Corp. Off:** Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India

**Tel:** +91-80-6784 0000 **Fax:** +91 80 6784 0700

**Regd Off:** 'Cyber One', Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India

**Tel:**+91-22-2789 2924/ 3199

corpcomm@strides.com; www.strides.com

**Disclosure under Regulation 30 of the Securities and Exchange Board of India  
(Listing Obligations and Disclosure Requirements) Regulation, 2015**

**Divestment of a dormant step-down whollyowned subsidiary of the Company**

#	Particulars
a)	<p><b>Amount and percentage of turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year</b></p> <p>As part of right sizing of group entities and eliminating dormant entities, Strides Pharma International Limited, a whollyowned subsidiary of the Company, has entered into a Share Transfer Agreement dated June 16, 2025, for divestment of its 100% shareholding in Strides CIS Limited, Cyprus to a third party.</p> <p>Strides CIS Limited, Cyprus was a dormant company and its financial parameters as at March 31, 2025 is as under:</p> <ul style="list-style-type: none"> <li>Revenue from operations: NIL</li> <li>Networth: Negligible as compared to the consolidated Networth of Strides Pharma Science</li> </ul>
b)	<p><b>Date on which Agreement for Sale has been entered into</b></p> <p>June 16, 2025</p>
c)	<p><b>Expected Date of Completion of Sale/ Disposal</b></p> <p>Simultaneous with the execution of Share Transfer Agreement</p>
d)	<p><b>Consideration received from such Sale/ Disposal</b></p> <p>USD 100/-</p>
e)	<p><b>Brief details of Buyers and Whether any of the Buyers belong to Promoter/ Promoter Group/ Group companies. If yes, details thereof</b></p> <p>Buyers: Mr. Sarvesh Bhargava and his spouse Mrs. Ranjana Bhargava, both acquiring 50% stake each in Strides CIS Limited.</p> <p>Sarvesh is a resident of UK and CEO &amp; Managing Director of M. Biotech Limited, a UK based Pharma company.</p> <p>Buyers are not related to any of the Promoter/ Promoter Group/ Group Companies of Strides Pharma Science Limited.</p>

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

**Corp. Off:** Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India

**Tel:** +91-80-6784 0000 **Fax:** +91 80 6784 0700

**Regd Off:** 'Cyber One', Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India

**Tel:**+91-22-2789 2924/ 3199

corpcomm@strides.com; www.strides.com

<b>f)</b>	<b>Whether transaction would fall within Related Party Transactions? If yes, whether the same is done at “Arms’ length”</b>
	No
<b>g)</b>	<b>Whether sale, lease or disposal of the undertaking is outside Scheme of Arrangement?  If yes, details of the same including compliance with regulation 37A of LODR Regulations</b>
	Not Applicable
<b>h)</b>	<b>Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slump sale.  <i>For the purpose of this sub-clause, "slump sale" shall mean the transfer of one or more undertakings, as a result of the sale for a lump sum consideration, without values being assigned to the individual assets and liabilities in such sales.</i></b>
	Not Applicable

\*\*\*\*\*

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

**Corp. Off:** Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India

**Tel:** +91-80-6784 0000 **Fax:** +91 80 6784 0700

**Regd Off:** ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India

**Tel:**+91-22-2789 2924/ 3199

corpcomm@strides.com; www.strides.com